vaccine

RFK Jr.’s anti-vaccine panel realizes it has no idea what it’s doing, skips vote

ACIP, CDC, health, hepatitis B, Rober F. Kennedy Jr., vaccine / DJ Henderson / September 19, 2025

With a lack of data and confusing language, the panel tabled the vote indefinitely.

Catherine Stein, far right, speaks during a meeting of the CDC’s Advisory Committee on Immunization Practices on September 18, 2025 in Chamblee, Georgia. Credit: Getty | Elijah Nouvelage

The second day of a two-day meeting of the Advisory Committee on Immunization Practices—a panel currently made up of federal vaccine advisors hand-selected by anti-vaccine activist Robert F. Kennedy, Jr.—is off to a dramatic start, with the advisors seemingly realizing they have no idea what they’re doing.

The inexperienced, questionably qualified group that has espoused anti-vaccine rhetoric started its second day of deliberations by reversing a vote taken the previous day on federal coverage for the measles, mumps, rubella, and varicella (MMRV) vaccine. Yesterday, the group voted to restrict access to MMRV, stripping recommendations for its use in children under age 4. While that decision was based on no new data, it passed with majority support of 8–3 (with one abstention). (For an explanation of that, see our coverage of yesterday’s part of the meeting here.)

But puzzlingly, they then voted to uphold access and coverage of MMRV vaccines for children under age 4 if they receive free vaccines through the federal Vaccines for Children program, which covers about half of American children, mostly low-income. The discrepancy projected the idea that the alleged safety concerns that led the panel to rescind the recommendation for MMRV generally, somehow did not apply to low-income, vulnerable children. The vote also created significant confusion for VFC coverage, which typically aligns with recommendations made by the panel.

Today, Kennedy’s ACIP retook the vote, deciding 9-0 (with three abstentions) to align VFC coverage with their vote yesterday to strip the recommendation for MMRV in young children.

Hepatitis B vaccine newborn dose

Next, they moved to a vote they failed to take yesterday as scheduled—a vote to strip a recommendation for a dose of hepatitis B vaccine that is currently recommended to be given universally on the first day of a baby’s life. Instead, the proposed recommendation would be to wait at least a month before the first dose—opening a window for a highly infectious disease that leads to chronic liver disease and cancer—unless the baby’s mother tested positive for the virus.

While it initially seemed that the panel was poised to approve the change, cracks in the plan began to appear quickly this morning, as some members of the panel noted that the proposed recommendation made no sense and was based on zero data.

Joseph Hibbeln, a psychiatrist on the panel, raised the obvious concern yesterday, saying: “I’m unclear if we’ve been presented with any safety or data comparing before one month to after one month, and I’m wondering why one month was selected as our time point and if there are data to help to inform us if there’s greater risk of adverse effects before one month or after one month at all, let alone in negative mothers.”

There was no data comparing the risks and benefits of moving the first dose from the day of birth to any other time point. And there is no data suggesting that such a move would be more or less safe.

Adam Langer, Acting Principal Deputy Director of the CDC’s National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention, stressed in his presentation on the safety data yesterday, that the vaccine is safe—there are no safety concerns for giving a dose at birth. Adverse side effects are rare, he said, and when they do occur, they’re mild. “The worst adverse event you could imagine, anaphylaxis, has been very rarely reported at only 1.1 cases per 1 million vaccine doses administered.”

Langer gave a clear explanation for why newborns are vaccinated at day one. Hepatitis B, which primarily affects the liver, spreads via bodily fluids and can live on surfaces for up to seven days. It can spread easily; only a tiny microscopic amount of blood or fluid is enough for a child to be infected. For some, an infection can be short-lived, but for others it can become chronic, which leads to liver disease, cirrhosis, liver transplant, and liver cancer. The risk of the infection becoming chronic increases with the younger someone is when they’re infected.

Benefits and harms

Newborns who get hepatitis B from their mothers at birth have a 90 percent chance of developing a chronic infection, and 25 percent of those children will die prematurely from the disease. Up to 16 percent of pregnant women in the US are not tested for hepatitis B during pregnancy. Newborns and babies can also get infected from other people in their family or household, given hepatitis B’s infectiousness. Prior to the universal birth dose recommendation, a study of US-born children born to immigrant mothers found that 7 percent to 11 percent of them had hepatitis B while their mothers were negative. This highlights that unvaccinated babies and children can pick up the infection from family or the community.

Part of the reason for this is the elusiveness of the disease. While about 2.4 million people in the US are infected with hepatitis B, about 50 percent of those infected do not know that they’re infected.

In 1991, ACIP began recommending universal hepatitis B vaccination at birth; acute hepatitis B cases then fell from around 18,000 to about 5,500 in 2005 to about 2,200 in 2023. Since 2018, ACIP has recommended universal Hep B vaccination for all newborns within 24 hours of birth.

In the discussion, panel members pushed back on the universal birth dose, arguing that if mothers tested negative, there was little to no risk—downplaying the risk of other family or community exposure and assuming that test coverage could increase to 100 percent. There was a lot of discussion of why some women aren’t tested and if doctors can just try to assess whether there’s a risk that a family member might have the infection—even if those family members don’t know themselves that they’re infected.

Data and trust

Langer acknowledged there might be ways to assess risk from at least the mother in the 24-hour window after birth—”or,” he suggested, “you cannot have to worry about all of those different things that could go wrong, and you could simply give the vaccine because there is no data available that says that there is any harm that would come to a newborn compared to a one-month-old infant [getting the vaccine.]”

He summed up the discussion succinctly: “The only thing that we’re discussing here is if there’s some benefit or removal of harm that comes from waiting a month. And I have not seen any data that says that there is any benefit to the infant of waiting a month, but there are a number of potential harms to the infant of waiting a month.”

Panel member Robert Malone, who has falsely claimed that COVID-19 vaccines cause a form of AIDS, explained that the proposed change for the hep B vaccination was not due to any safety concern or evidence-based reason, but about trust among parents who have been exposed to vaccine misinformation.

“The signal that is prompting this is not one of safety, it is one of trust,” Malone said yesterday. “It is one of parents uncomfortable with this medical procedure being performed at birth in a rather unilateral fashion without significant informed consent at a time in particular when there has been a loss of trust in the public health enterprise and vaccines in general.”

Dashed decisions

But the questions and uncertainties of the proposed recommendation and the data behind it dogged the committee again this morning.

This morning, the voting language was put on a slide and immediately drew criticism. The language was:

If a mother tests [hepatitis B]-negative:

The first dose of the Hepatitis B vaccine is not given until the child is at least one month old.

Infants may receive a dose of Hepatitis B vaccine before one month according to individual based decision-making. *

*Also referred to as shared clinical decision-making.

Hibbeln, the psychiatrist, again pushed back, this time noting that the language of the change is confusing. “You can’t say don’t give it and then give an opportunity to give it,” he said, arguing that shared clinical decision-making is, essentially, all or nothing.

Discussion quickly spiraled, with another member questioning whether there was any data presented at all on the proposed recommendation. There was a fast motion to table the vote indefinitely, and the motion to table passed in a speedy vote of 11–1, with the ACIP chair, Martin Kulldorff, being the only holdout.

For the rest of the day, the panel is discussing COVID-19 vaccines. Stay tuned.

Beth is Ars Technica’s Senior Health Reporter. Beth has a Ph.D. in microbiology from the University of North Carolina at Chapel Hill and attended the Science Communication program at the University of California, Santa Cruz. She specializes in covering infectious diseases, public health, and microbes.

RFK Jr.’s anti-vaccine panel realizes it has no idea what it’s doing, skips vote Read More »

In new level of stupid, RFK Jr.’s anti-vaccine advisors axe MMRV recommendation

ACIP, CDC, health, MMR, mmrv, robert f kennedy jr, vaccine / DJ Henderson / September 19, 2025

The vote to strip the recommendation came after a day of inept discussion.

An MMR and VAR vaccine ready for a pediatric vaccination at Kaiser Permanente East Medical offices in Denver in 2015. Credit: Getty | Joe Amon

The panel of vaccine advisors hand-selected by anti-vaccine activist Robert F. Kennedy Jr. voted on Thursday to change the federal vaccine recommendations for children, removing safe, well-established vaccine doses from current schedules and realizing Kennedy’s anti-vaccine agenda to erode federal vaccine policy and sow distrust.

Specifically, the panel—the Advisory Committee on Immunization Practices (ACIP)—voted to remove the Centers for Disease Control and Prevention’s previous recommendation for use of a measles, mumps, rubella, varicella (chickenpox) MMRV combination vaccine for children under 4 years old.

The context

In June, Kennedy fired all 17 highly qualified, highly vetted members of ACIP and quickly replaced them with seven questionable members, who largely did not have subject matter expertise. Moreover, many of them have clearly expressed anti-vaccine rhetoric and skepticism about pandemic responses and COVID-19 vaccines. At least two new members have been paid witnesses in trials against vaccine makers, a clear conflict of interest. Earlier this week, Kennedy added five additional members, who raise the same anti-vaccine concerns as the first group.

In the meeting today—the first of two all-day meetings—members made clear their inexperience and lack of expertise in evaluating vaccine policy. They asked basic questions about study data and analysis—such as asking what a “low confidence” designation means—and claimed CDC presentations lacked critical data when, in fact, a CDC scientist had just presented the exact data in question.

The first half of the day focused on the MMRV vaccine, while the second half focused on a newborn dose of the hepatitis B (hep B) vaccine. A vote was initially scheduled for that vaccine today, too, but was postponed after the panel decided to change the wording of the voting question. They meet again tomorrow to vote on the hep B recommendation as well as recommendations for this year’s COVID-19 vaccine. Ars Technica will have coverage of the second half of the meeting tomorrow, along with a report on the hepatitis B discussion today.

MMRV vaccine change

For the MMRV vaccine, the panel rehashed an issue that vaccine experts had thoroughly examined years ago. Currently, the CDC recommends children get vaccinated against measles, mumps, rubella, and varicella (chickenpox) twice—one dose at 12 to 15 months, and a second dose between the ages of 4 and 6 years.

In 2005, the Food and Drug Administration approved a combo shot for all four—the MMRV vaccine—which provided an alternative to the previous method of giving an MMR vaccine dose (against measles, mumps, and rubella) plus a separate varicella vaccine dose at the same time. (This vaccination strategy is shorthanded as MMR + V.) Thus, the MMRV combo shot meant one fewer shot for children. But, in 2008, post-market data suggested that the MMRV shot might have a slightly higher risk of causing febrile seizures (seizures associated with fevers), which is a very low risk with the MMR + V separate shots.

Febrile seizures are a somewhat common reaction in young children; this type of seizure almost entirely occurs in children under age 5 years, most often striking between 14 and 18 months. The seizures are short, usually less than a minute or two, and they can be caused by essentially anything that can cause a fever—ear infections, vaccines, the flu, etc. For parents, a febrile seizure can be very scary and lead them to bring their child to a doctor or hospital. However, febrile seizures are almost always harmless—the prognosis is “excellent,” as CDC staff experts noted. Nearly all children fully recover with no long-term problems. By age 5, up to 5 percent of all children have had a febrile seizure at some point, for some reason.

Low risks

In post-market studies of the MMRV vaccine, it was very clear that a slightly increased risk of febrile seizures was only linked to the first dose (given at 12 to 15 months, not the second, given at 4 to 6 years). In studies of over 400,000 children, data found that the risk of a febrile seizure after a first-dose MMRV vaccine was 7 to 8.5 seizure cases for every 10,000 vaccinations. That’s compared to 3.2 to 4.2 seizure cases in 10,000 vaccinations with MMR + V. In all, a first-dose MMRV vaccine had about one additional febrile seizure per 2,300 to 2,600 children vaccinated compared with MMR + V.

In 2009, CDC vaccine experts reviewed all the data and updated the vaccine recommendation. They maintained that MMRV and the MMR+V vaccinations are still both safe, effective, and recommended at both vaccination time points. But, they added the nuance that there is a preference (or a default, basically) for using the MMR + V shots for the first dose, unless a parent expressly wanted the MMRV vaccine for that first dose. This skirted the slightly increased risk of febrile seizure in young children, without entirely taking away the option if a parent prioritized fewer jabs and wanted the MMRV. For the second dose, again, both MMRV and MMR + V are options, but the CDC stated a preference for the one-shot MMRV.

Since then, about 85 percent of vaccinated children have gotten MMR + V for their first dose shots, with the other 15 percent getting the MMRV vaccine.

Inept discussion

In the discussion today, Kennedy’s members seemed to have little grasp of the issue at hand and the clinical significance of febrile seizures generally. They continued to circle back to unfounded concerns about febrile seizures and fringe theories about potential long-term effects.

Cody Meissner, a pediatric professor at Dartmouth’s Geisel School of Medicine who has served on ACIP in the past—arguably the most qualified of Kennedy’s new lineup—was bewildered at why the committee was rehashing the issue addressed years ago. “This discussion is really a déjà vu for me,” he said. Yet, while Meisner felt the issue was settled and pediatricians were well-equipped to calm parents’ fears about febrile seizures, the other members could not be swayed. They claimed, without evidence, that parents of children who have febrile seizures after a vaccine would be less likely to get future vaccines.

As the committee seemed to be leaning toward removing the recommendation for MMRV for the first dose, Jason Goldman, president of the American College of Physicians, who attended the meeting as a liaison, pushed back strongly. He pointed out that—as with the last time Kennedy’s ACIP met—they were not following the standard framework for making and changing recommendations.

“Are we going to have a thoroughly vetted evidence-to-recommend framework presentation that looks at all the harms benefits, acceptability, feasibility—with input from practicing clinicians and liaisons in order to make an informed decision?” Goldman asked. “I would argue that this recommendation is going to create more confusion among the public.”

Goldman noted that if the committee rescinds the recommendation for MMRV for children under 4, the shot would no longer be covered by the Vaccines for Children (VFC) Program, a federal program for Medicaid-eligible and under- or uninsured kids, which covers about half of American children.

“And finally, you are taking away the choice of parents to have informed consent and discussion with their physician on what they want to do for the health and benefit of their children,” Goldman said. “So, I urge this committee not to change the recommendations if they truly want to give the power to the parents to decide what is best for their child and allow them to make the choice in consultation with their physicians.”

Voting confusion

In the end, Kennedy’s panel voted 8–3 (with one abstention) to not recommend MMRV for children under age 4, meaning the MMRV vaccine could potentially no longer be available for some children under age 4. Private insurance companies are required to cover ACIP-recommended vaccines, so this move strips the recommendation and that coverage requirement.

But, anticipating such a change, AHIP, a trade organization representing insurance companies, put out a statement earlier this week suggesting that they would still cover the MMRV vaccine for children under 4, even if it’s not required.

“Health plans will continue to cover all ACIP-recommended immunizations that were recommended as of September 1, 2025, including updated formulations of the COVID-19 and influenza vaccines, with no cost-sharing for patients through the end of 2026,” the statement reads.

But, there’s more: In a second vote today, ACIP voted 8–1 (with three abstentions) against changing VFC coverage for MMRV. Therefore, the VFC program will continue to cover MMRV vaccines for children under age 4. This is a split from standard policy that is likely to spur confusion, because VFC typically goes with ACIP recommendations. Also, Medicaid’s Children’s Health Insurance Program (CHIP) has to follow the ACIP vaccine recommendation and thus will no longer cover MMRV for children under age 4 covered by CHIP.

One of the abstentions on the VFC coverage vote was Meissner, who didn’t want to strip the recommendation or the VFC coverage but was entirely confused by how this would work in practice.

In new level of stupid, RFK Jr.’s anti-vaccine advisors axe MMRV recommendation Read More »

Child dies of horrifying measles complication in Los Angeles

CDC, child, death, health, Infectious disease, Los Angeles, measles, sspe, vaccine / Beth Washington / September 12, 2025

A child in Los Angeles has died of a measles-related brain disorder stemming from an infection in infancy, the Los Angeles County health department reported Thursday.

Specifically, the child died of subacute sclerosing panencephalitis (SSPE), a rare but always fatal complication that strikes years after an initial measles infection. The health department’s announcement offered few details about the child, including the child’s age, but said that the child had contracted the virus before they were old enough to be vaccinated against measles. The first of two recommended doses of measles, mumps, and rubella (MMR) vaccine is given between 12 and 15 months.

“This case is a painful reminder of how dangerous measles can be, especially for our most vulnerable community members,” Muntu Davis, a Los Angeles County health officer, said in a statement. “Infants too young to be vaccinated rely on all of us to help protect them through community immunity. Vaccination is not just about protecting yourself—it’s about protecting your family, your neighbors, and especially children who are too young to be vaccinated.”

SSPE is caused by a persistent measles infection in the central nervous system. Children infected with the virus may go through the standard disease progression—flu-like symptoms, high fever, the telltale rash—and then appear to fully recover. But, for a small few, the virus remains, and SSPE emerges years later, often seven to 10 years after the initial infection.

The Los Angeles health department noted that SSPE generally affects about 1 in 10,000 people with measles, but the risk may be much higher—about 1 in 600—for those who get measles as infants, such as the child who recently died.

With widespread vaccination, which led to measles being declared eliminated from the US in 2000, SSPE has virtually disappeared in the US. However, with vaccination rates slipping and anti-vaccine misinformation and views gripping the country, health experts fear seeing more of these devastating cases. Already, the US measles case count for the year is at a 33-year high, and two other children, as well as an adult, died from the acute infection this year.

Child dies of horrifying measles complication in Los Angeles Read More »

RFK Jr. defends $500M cut for mRNA vaccines with pseudoscience gobbledygook

antigen, flu, health, kennedy, pandemic, SARS-CoV-2, vaccine, virus / Shannon Garcia / August 7, 2025

He clearly has no idea what antigenic shift means.

US Secretary of Health and Human Services Robert F. Kennedy Jr. testifies before the Senate Committee on Health, Education, Labor, and Pensions on Capitol Hill on May 20, 2025 in Washington, DC. Credit: Getty | Tasos Katopodis

If anyone needed a reminder that US health secretary and fervent anti-vaccine advocate Robert F. Kennedy Jr. has no background in science or medicine, look no further than the video he posted on social media Tuesday evening.

In the two-and-a-half-minute clip, Kennedy announced that he is cancelling nearly $500 million in funding for the development of mRNA-based vaccines against diseases that pose pandemic threats. The funding will be clawed back from 22 now-defunct contracts awarded through the federal agency tasked with developing medical countermeasures to public health threats. The agency is the Biomedical Advanced Research and Development Authority (BARDA).

Kennedy is generally opposed to vaccines, but he is particularly hostile to mRNA-based vaccines. Since the remarkably successful debut of mRNA COVID-19 vaccines during the COVID-19 pandemic—which were developed and mass-produced with unprecedented speed—Kennedy has continually disparaged and spread misinformation about them.

In the video on Tuesday, Kennedy continued that trend, erroneously saying that, “as the pandemic showed us, mRNA vaccines don’t perform well against viruses that infect the upper respiratory tract.” In reality, COVID-19 vaccines are estimated to have saved more than 3 million lives in the US in just the first two years of the pandemic and additionally prevented more than 18 million hospitalizations in the US in that time. Nearly all COVID-19 vaccines used in the US are mRNA-based.

However, Kennedy’s video only went more off the rails from there. He continued on with this nonsensical explanation:

Here’s the problem: mRNA only codes for a small part of viral proteins usually a single antigen. One mutation, and the vaccine becomes ineffective. This dynamic drives a phenomenon called antigenic shift meaning that the vaccine paradoxically encourages new mutations and can actually prolong pandemics as the virus constantly mutates to escape the protective effects of the vaccine.

Fact-check

To unpack this nonsense, let’s start with how mRNA-based vaccines work. These vaccines deliver a snippet of genetic code—in the form of messenger RNA (mRNA)—to cells. Our cells then translate that mRNA code into a protein that the immune system can, essentially, use for target practice, producing antibodies and cell-based responses against it. After that, if the immune system ever encounters that snippet on an actual invading virus or other germ, it will then recognize it and mount a protective response. Such snippets of germs or other harmful things that can prompt an immune response are generally called antigens.

In the case of COVID-19 vaccines, the mRNA snippet codes for a portion of the SARS-CoV-2 virus’s spike protein, which is a critical external protein that the virus uses to attach to and infect cells. That portion of the spike protein is considered an antigen.

SARS-CoV-2, including its spike protein, is continually evolving, regardless of whether people are vaccinated or not, let alone what type of vaccine they’ve received. The virus racks up mutations as it continuously replicates. Some of these mutations help a virus evade immune responses, whether they’re from vaccination or previous infection. These immune-evading mutations can accumulate and give rise to new variants or strains, making it part of a process called antigenic drift (not shift). Antigenic drift does reduce the efficacy of vaccines over time. It’s why, for example, people can get influenza repeatedly in their lifetimes, and why flu shots are updated annually. However, it does not mean that vaccines are immediately rendered ineffective upon single mutations, as Kennedy says.

For example, the current leading SARS-CoV-2 variant in the US is NB.1.8.1, which has six notable mutations in its spike protein compared to the previous leading variant, LP.8.1. Further, NB.1.8.1 has seven notable spike mutations compared to the JN.1 variant, an ancestor for this line of variants. Yet, studies suggest that current mRNA COVID-19 vaccines targeting JN.1 are still effective against NB.1.8.1. In fact, the Food and Drug Administration, in line with its expert advisors, left open the possibility that vaccine makers could carry over the same JN.1-targeting seasonal COVID-19 vaccine formula from last season for use in this season.

Drift vs. shift

While antigenic drift is an accumulation of small, immune-evading mutations over time, Kennedy mentioned antigenic shift, which is something different. Antigenic shift is much more dramatic, infrequent, and is typically discussed in the context of influenza viruses, which have segmented genomes. Antigenic shift is often defined as “the reassortment of viral gene segments between various influenza viruses of human or zoological origin, which leads to the emergence of new strains.” The Centers for Disease Control and Prevention gives an example of such a shift in 2009. That’s when a new influenza virus with a collection of genome segments from influenza viruses found in North American swine, Eurasian swine, humans, and birds emerged to cause the H1N1 pandemic.

In the video, Kennedy went on to muddle these concepts of drifts and shifts, saying:

Millions of people maybe even you or someone you know caught the omicron variant despite being vaccinated, that’s because a single mutation can make mRNA vaccines ineffective.

Among the COVID-19 variants that have risen to dominance only to be quickly usurped, there’s usually a small handful of mutations—like the examples above with six or seven mutations in the spike protein. But omicron was a different story. Omicron emerged carrying an extremely large suite of mutations—there were 37 mutations in its spike protein compared to its predecessors. Kennedy’s suggestion that it rose to prominence because of a single mutation is egregiously false.

However, due to the extreme number of mutations, some researchers have suggested that omicron does represent an antigenic shift for SARS-CoV-2. Although the pandemic virus—which is a coronavirus—does not have a segmented genome, the “magnitude of Omicron-mediated immune evasion” fits with an antigenic shift, the researchers said.

“Highly vulnerable”

While long-term drifts and rare shifts can reduce the effectiveness of vaccines, creating the need for updated shots, the point only bolsters the case for using mRNA vaccines in the event of another health emergency. Currently, no other vaccine platform beats the development and production speeds of mRNA vaccines. Kennedy said that instead of mRNA vaccines, he’ll shift to developing vaccines using strategies like whole-virus vaccines. But this decades-old strategy requires growing up large supplies of virus in eggs or cell culture, which takes months longer than mRNA vaccines. Further, using whole, inactivated viruses can often produce more side effects than other types of vaccines because they include more antigens.

Overall, experts were aghast that Kennedy has abandoned mRNA vaccines for pandemic preparedness programs. One expert, who asked not to be named for fear of reprisal, told Stat News: “It’s self-evident that this is the single best technology we have now to rapidly produce a vaccine for the largest number of people,” the expert said. “And you are throwing away a technology which was exceedingly valuable in saving lives during the most recent pandemic.”

Michael Osterholm, director of the University of Minnesota’s Center for Infectious Disease Research and Policy, told the outlet that the move “leaves us highly vulnerable. Highly vulnerable.”

RFK Jr. defends $500M cut for mRNA vaccines with pseudoscience gobbledygook Read More »

Large study squashes anti-vaccine talking points about aluminum

ACIP, aluminum, anti-vaccine, health, robert f kennedy jr, vaccine / Shannon Garcia / July 16, 2025

A sweeping analysis of health data from more than 1.2 million children in Denmark born over a 24-year period found no link between the small amounts of aluminum in vaccines and a wide range of health conditions—including asthma, allergies, eczema, autism, and attention deficit-hyperactivity disorder (ADHD).

The finding, published in the Annals of Internal Medicine, firmly squashes a persistent anti-vaccine talking point that can give vaccine-hesitant parents pause.

Small amounts of aluminum salts have been added to vaccines for decades as adjuvants, that is, components of the vaccine that help drum up protective immune responses against a target germ. Aluminum adjuvants can be found in a variety of vaccines, including those against diphtheria, tetanus, and pertussis, Haemophilus influenzae type b (Hib), and hepatitis A and B.

Despite decades of use worldwide and no clear link to harms, concern about aluminum and cumulative exposures continually resurfaces—largely thanks to anti-vaccine advocates who fearmonger about the element. A leader of such voices is Robert F. Kennedy Jr, the current US health secretary and an ardent anti-vaccine advocate.

In a June 2024 interview with podcaster Joe Rogan, Kennedy falsely claimed that aluminum is “extremely neurotoxic” and “give[s] you allergies.” The podcast has racked up nearly 2 million views on YouTube. Likewise, Children’s Health Defense, the rabid anti-vaccine organization Kennedy created in 2018, has also made wild claims about the safety of aluminum adjuvants. That includes linking it to autism, despite that many high-quality scientific studies have found no link between any vaccines and autism.

While anti-vaccine advocates like Kennedy routinely dismiss and attack the plethora of studies that do not support their dangerous claims, the new study should reassure any hesitant parents.

Clear data, unclear future

For the study, lead author Niklas Worm Andersson, of the Statens Serum Institut in Copenhagen, and colleagues tapped into Denmark’s national registry to analyze medical records of over 1.2 million children born in the country between 1997 and 2018. During that time, new vaccines were introduced and recommendations shifted, creating variation in how many aluminum-containing vaccines children received.

Large study squashes anti-vaccine talking points about aluminum Read More »

Moderna says mRNA flu vaccine sailed through trial, beating standard shot

anti-vaccine, flu shot, health, moderna, mRNA, robert f kennedy jr, vaccine / 9u50fv / July 2, 2025

An mRNA-based seasonal flu vaccine from Moderna was 27 percent more effective at preventing influenza infections than a standard flu shot, the company announced this week.

Moderna noted that the new shot, dubbed mRNA-1010, hit the highest efficacy target that it set for the trial, which included nearly 41,000 people aged 50 and above. Participants were randomly assigned to receive either mRNA-1010 or a standard shot and were then followed for about six months during a flu season.

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 percent higher in participants who were aged 65 years or older. Previous trial data showed that mRNA-1010 generated higher immune responses in participants than both regular standard flu shots and high-dose flu shots.

The company noted that the positive results for the new trial come in the wake of one of the worst flu seasons in years. During the 2024–2025 flu season, the Centers for Disease Control and Prevention estimates that 770,000 people in the US were hospitalized for the flu.

“Today’s strong Phase 3 efficacy results are a significant milestone in our effort to reduce the burden of influenza in older adults,” Moderna CEO Stéphane Bancel said in a statement. “The severity of this past flu season underscores the need for more effective vaccines. An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for COVID-19 combination vaccines.”

Moderna says mRNA flu vaccine sailed through trial, beating standard shot Read More »

Anti-vaccine quack hired by RFK Jr. has started work at the health department

anti-vaccine, autism, health, robert f kennedy jr, thimerosal, vaccine / DJ Henderson / June 7, 2025

Outside researchers can request access to VSD data by submitting study proposals to the CDC. The Geiers have, in the past, gained access. But, they lost that access at least twice, the Journal reported. In 2004, the CDC kicked the Geiers out after officials determined that they had misrepresented their plans for the data when they initially submitted their proposal to the CDC. They were barred again in 2006.

Now an HHS employee, Geier is seeking access to the data once again. The Journal reports that Kennedy has assigned researchers at the National Institutes of Health to assist Geier and that those NIH employees have sent a request to the CDC to hand over all of VSD’s data. This request reportedly caused alarm at the CDC and the project’s health care sites around the country, which are concerned about protecting the security of private patient data.

It’s unclear whether Geier has regained access to the data. But people familiar with the matter told the Journal that Geier aims to reanalyze the CDC’s data on thimerosal to try to prove a link to autism. The sources also said that Geier is interested in proving that the CDC is corrupt.

In the May hearing, Kennedy, who also supports the debunked claim that vaccines cause autism, defended Geier. Kennedy said that “there has been a lot of monkey business with the VSD” and that Geier is “the only living independent scientist” who has seen the data and can determine if it has been altered. (Hassan interjected that Geier is not a scientist.) Kennedy also falsely claimed that a court overturned the medical board’s finding that he had practiced medicine without a license and awarded Geier $5 million.

That did not happen. But Kennedy may have been referring to the fact that Mark Geier filed a lawsuit against the medical board over a 2012 cease-and-desist order that alleged he improperly prescribed medication for himself, his wife, and his son while his medical license was suspended. Mark Geier sued the board, saying the order was malicious because it contained personal information, including the medications Geier had prescribed. A Circuit Court sided with the Geiers, awarding them nearly $5 million in total. But the win and the award were overturned on appeal in 2019.

Anti-vaccine quack hired by RFK Jr. has started work at the health department Read More »

New RSV vaccine, treatment linked to dramatic fall in baby hospitalizations

antibody, health, RSV, vaccine / Shannon Garcia / May 9, 2025

For the new study, CDC researchers looked at RSV hospitalization rates across two different RSV surveillance networks of hospitals and medical centers (called RSV-NET and NVSN). They compared the networks’ hospitalization rates in the 2024–2025 RSV season to their respective rates in pre-pandemic seasons between 2018 and 2020. The analysis found that among newborns (0–2 months), RSV hospitalizations fell 52 percent in RSV-NET and 45 percent in NVSN compared with the rates from the 2018–2020 period. However, when the researcher excluded data from NVSN’s surveillance site in Houston—where the 2024–2035 RSV season started before the vaccine and treatment were rolled out—there was a 71 percent decline in hospitalizations in NVSN.

For a broader group of infants—0 to 7 months old—RSV-NET showed a 43 percent drop in hospitalizations in the 2024–2025 RSV season, and NVSN saw a 28 percent drop. Again, when Houston was excluded from the NVSN data, there was a 56 percent drop.

Lastly, the researchers looked at hospitalization rates for toddlers and children up to 5 years old, who wouldn’t have been protected by the new products. There, they saw RSV hospitalization rates were actually higher in the 2024–2025 season than in the pre-pandemic years. That suggests that the latest RSV season was more severe, and the drops in infant hospitalizations may be underestimates.

New RSV vaccine, treatment linked to dramatic fall in baby hospitalizations Read More »

Mom of child dead from measles: “Don’t do the shots,” my other 4 kids were fine

anti-vaccine, children's health defense, health, kennedy, measles, MMR, vaccine / Shannon Garcia / March 21, 2025

Cod liver oil contains high levels of vitamin A, which is sometimes administered to measles patients under a physician’s supervision. But the supplement is mostly a supportive treatment in children with vitamin deficiencies, and taking too much can cause toxicity. Nevertheless, Kennedy has touted the vitamin and falsely claimed that good nutrition protects against the virus, much to the dismay of pediatricians.

“They had a really good, quick recovery,” the mother said of her other four children, attributing their recovery to the unproven treatments.

Tragic misinformation

Most children do recover from measles, regardless of whether they’re given cod liver oil. The fatality rate of measles is nearly 1 to 3 in 1,000 children, who die with respiratory (e.g., pneumonia) or neurological complications from the virus, according to the Centers for Disease Control and Prevention.

Tommey noted that the sibling who died didn’t get the alternative treatments, leading the audience to believe that this could have contributed to her death. She also questioned what was written on the death certificate, noting that the girl’s pneumonia was from a secondary bacterial infection, not the virus directly, a clear effort to falsely suggest measles was not the cause of death and downplay the dangers of the disease. The parents said they hadn’t received the death certificate yet.

Tommey then turned to the MMR vaccine, asking if the mother still felt that it was a dangerous vaccine after her daughter’s death from the disease, prefacing the question by claiming to have seen a lot of “injury” from the vaccine. “Do you still feel the same way about the MMR vaccine versus measles?” she asked.

“Yes, absolutely; we would absolutely not take the MMR. The measles wasn’t that bad, and they got over it pretty quickly,” the mother replied, speaking again of her four living children.

“So,” Tommey continued, “when you see the fearmongering in the press, which is what we want to stop, that is why we want to get the truth out, what do you say to the parents who are rushing out, panicking, to get the MMR for their 6-month-old baby because they think that that child is going to die of measles because of what happened to your daughter?”

Mom of child dead from measles: “Don’t do the shots,” my other 4 kids were fine Read More »

Report: mRNA vaccines are in RFK Jr’s crosshairs; funding in question

grant, health, HHS, mRNA, mRNA vaccines, NIH, rfk jr, robert f kennedy jr, vaccine / Beth Washington / March 18, 2025

Ars Technica has reached out to the NIH and HHS for comment and will update this story with any new information provided. The agencies did not respond to comment requests from KFF.

Kennedy’s misinformation

Before becoming the top health official in America, Kennedy had long railed against vaccines, becoming one of the world’s most prominent anti-vaccine advocates and most prolific spreaders of misinformation and disinformation about vaccines. A 2019 study found Kennedy was the single leading source of anti-vaccine ads on Facebook. Kennedy subsequently faced bans from YouTube, Facebook, and Instagram for spreading misinformation.

Researchers directly blame Kennedy and the Trump administration for the attack on vaccine research.

“Kennedy’s war on vaccines has started,” the mRNA vaccine researcher in Philadelphia told KFF.

“There will not be any research funded by NIH on mRNA vaccines,” the scientist in New York similarly told the outlet. “MAGA people are convinced that these vaccines have killed and maimed tens of thousands of people. It’s not true, but they believe that.”

Kennedy has made various statements against vaccines generally, as well as mRNA vaccines specifically. He falsely claimed the vaccine causes severe harms, including causing neurodegenerative diseases, such as Parkinson’s. In 2021, during the height of the pandemic, Kennedy petitioned the Food and Drug Administration to revoke the authorization of COVID-19 vaccines and refrain from approving any future COVID-19 vaccines. A study in 2022, meanwhile, estimated that the vaccines had saved more than 3 million lives and prevented more than 18 million hospitalizations.

The NIH’s recent moves aren’t the first sign that Kennedy will use his powerful position to attack mRNA vaccines. Late last month, Bloomberg reported that HHS was considering canceling a $590 million grant to vaccine-maker Moderna to develop mRNA vaccines against potential pandemic influenza viruses. That includes the H5N1 virus that is currently devastating US poultry and spreading wildly in dairy cows.

An HHS spokesperson told media at the time that “while it is crucial that the US Department and Health and Human Services support pandemic preparedness, four years of the Biden administration’s failed oversight have made it necessary to review agreements for vaccine production.”

It remains unclear what is happening with that grant review. Moderna declined to comment when Ars reached out for any potential updates Monday.

Report: mRNA vaccines are in RFK Jr’s crosshairs; funding in question Read More »

US measles outlook is so bad health experts call for updating vaccine guidance

CDC, domestic, health, Infectious disease, international travel, measles, MMR, outbreaks, travel, vaccination, vaccine / DJ Henderson / March 16, 2025

With measles declared eliminated from the US in 2000 and national herd immunity strong, health experts have recommended that American children get two doses of the Measles, Mumps, and Rubella (MMR) vaccine—the first between the ages of 12 and 15 months and the second between the ages of 4 and 6 years, before they start school.

Before 12 months, vulnerable infants in the US have been protected in part by maternal antibodies early in infancy as well as the immunity of the people surrounding them. But if they travel to a place where population immunity is unreliable, experts recommend that infants ages 6 to 11 months get an early dose—then follow it up with the standard two doses at the standard times, bringing the total to three doses.

The reason they would need three—and the reason experts typically recommend waiting until 12 months—is because the maternal antibodies infants carry can interfere with the vaccine response, preventing the immune system from mounting long-lasting protection. Still, the early dose provides boosted protection in that 6-to-11-month interval.

In the past, this early, extra dose was recommended for infants traveling internationally—to countries that hadn’t achieved America’s enviable level of herd immunity and were vulnerable to outbreaks. But now, with US vaccination rates slipping, herd immunity becoming spotty, cases rising by the day, and outbreaks simmering in multiple states, the US is no longer different from far-off places that struggle with the extremely infectious virus.

In an article published today in JAMA, prominent health experts—including former Centers for Disease Control and Prevention Director Rochelle Walensky—call for the US to update its MMR recommendations to include the early, extra dose for infants who are not only traveling abroad, but domestically, to any areas where measles is a concern.

“With some local immunization levels inadequate to avert outbreaks and ongoing disease spread in various regions of the country, a dichotomy between domestic and international travel is not appropriate,” the experts write. “For many travel itineraries, there may even be a higher risk of measles exposure at the US point of departure than at the international destinations.”

Vaccinating at-risk infants early is critical to their own health—as well as the people around them, the experts note. “[I]nfants younger than one year face a heightened risk of severe measles-related complications such as pneumonia, encephalitis, and death. Younger infants are also at increased risk of developing subacute sclerosing panencephalitis (SSPE), a rare measles complication that has a high fatality rate and may surface years after initial infection,” according to the experts.

US measles outlook is so bad health experts call for updating vaccine guidance Read More »

Norovirus vaccine hints at defusing explosive stomach bug in early trial

health, Norovirus, Science, vaccine, vaxart / Beth Washington / March 7, 2025

Phase I study showed vaccine was safe and spurred immune responses in older people.

An electron micrograph of norovirus. Credit: Getty| BSIP

In an early clinical trial, an experimental norovirus vaccine given as a pill produced defensive responses exactly where it counts—in the saliva of older people most vulnerable to the explosive stomach bug.

The results, published this week in Science Translational Medicine, are another step in the long effort to thwart the gruesome germ, which finds a way to violently hollow out innards wherever people go—from restaurants to natural wonders and even the high seas. It’s a robust, extremely infectious virus that spreads via the nauseating fecal-oral route. Infected people spew billions of virus particles in their vomit and diarrhea, and shedding can last weeks. The particles aren’t easily killed by hand sanitizers and can linger on surfaces for up to two weeks. Exposure to as few as 10 virus particles can spark an infection. According to the Centers for Disease Control and Prevention, norovirus causes an average of between 19 and 21 million cases of acute gastroenteritis in the US every year, leading to 109,000 hospitalizations and 900 deaths. This racks up an economic burden estimated to be $2 billion to $10.6 billion.

Vaccine design

For most, the gut-busting bug is miserable but usually over in a few days. But older people—especially those with underlying medical conditions—are vulnerable to severe outcomes. About 90 percent of people who die from a norovirus infection are people age 65 or older who live in long-term care facilities.

For this reason, researchers have aimed to design a vaccine that’s sure to be effective in older people, who typically have weaker immune responses just from the aging process. But, of course, this makes the already daunting task of developing a vaccine yet harder—and norovirus poses some specific challenges. For one, there aren’t a lot of good laboratory models and animal systems to run norovirus experiments or test candidate drugs. For example, healthy mice infected with a mouse version of norovirus don’t develop any symptoms (lucky critters). Then there’s the fact that norovirus isn’t one virus; it’s many. There are 49 different genotypes of norovirus, which have been categorized into 10 “genogroups.” It’s unclear if protection against one genotype or genogroup will help protect against the others, and if so, by how much.

Currently, there are several norovirus vaccines in the works, at various stages with various designs. The one published this week is being developed by a San Francisco-based company called Vaxart and uses a proprietary oral delivery system. The pill includes a deactivated virus particle (an adenovirus), which can’t replicate in people but can deliver the genetic blueprints of two molecules into cells lining our intestines. One of the genetic blueprints it delivers tells the intestinal cells how to manufacture a protein found on the outside of norovirus particles, called VP.1. Once manufactured in the intestines, VP.1 can train the immune system to identify invading norovirus particles and attack them. The other genetic code included in the vaccine is for what’s called an “adjuvant,” which is basically a booster molecule that helps rev up immune responses.

While several other vaccines in the works are delivered by injections, producing systemic responses, the idea of the pill is to build up immune responses to norovirus directly where it invades and attacks—the mucosal lining of the digestive tract, including the mouth and intestines. There is some preliminary data suggesting that having antibodies against norovirus in saliva correlates with protection from the virus.

Good news

Vaxart has previously published Phase I trial data showing that its pill is safe and well-tolerated in healthy adults ages 18 to 49. The study, published in 2018, also indicated that the pill generated “substantial” systemic and mucosal antibodies against norovirus.

For the new study, Vaxart did a repeat Phase I trial with 65 older people—ages 55 to 80, broken into groups of 55 to 65, and 66 to 80. The participants were randomly assigned to get either a placebo (22) or a low (16), medium (16), or high (11) dose of the vaccine VXA-G1.1-NN, which targets one genotype of norovirus. Again, the vaccine was safe and well-tolerated. There were no serious side effects. The most common side effects were headache and fatigue, which were reported at about the same rates among the placebo and vaccinated groups.

Further, detailed examination of the participants’ immune responses showed not only systemic response, but responses in distant mucus membranes. In the blood, two types of antibodies (IgA and IgG) increased by several fold after vaccination compared with the placebo group. The group with the largest responses was the one that received the high dose.

A test that acts as a surrogate for neutralizing antibody responses to norovirus indicated that the antibodies spurred by the vaccine could block the virus. Additional tests found that cellular immune responses were also activated and that the systemic responses result in protection in places far from the intestines—namely the mouth and nose. Saliva tests and nasal swabs found significant jumps in secreted IgA against norovirus.

Immune responses were strongest in the first two months after vaccination and diminished over time, but some persisted for nearly seven months. When the scientists looked at differences between the two age groups (55–65 and 65–80), they didn’t see significant differences, suggesting the vaccine was equally effective in the older group.

Overall, the scientists at Vaxart concluded that the vaccine “has the potential to inhibit infection, viral shedding, and transmission.”

“Overall, VXA-G1.1-NN administration in older adults led to robust and durable immunogenicity detected both in circulation and multiple mucosal sites, an exciting outcome considering that diminished cellular and mucosal immunity are typical in older populations,” they wrote.

Not so good news

The outlook isn’t entirely rosy, though—there is some bad news. While immune responses rose in statistically significant measures during this small early-stage trial, it’s unclear if that equates to real-life protection. And there’s some good reason to be wary. In 2023, Vaxart released results of a challenge study, in which 141 brave souls (76 vaccinated and 65 given a placebo) were deliberately exposed to norovirus to see if the vaccine was protective. The results were weak: 53 placebo-group members (81.5 percent) became infected with norovirus, as determined by a PCR test looking for genetic evidence of the virus in their stool—and so did 76 vaccinated people (60 percent). That worked out to the vaccine offering only a 29 percent lower relative risk of getting infected. Looking at whether infected people developed symptoms of acute gastroenteritis, the vaccine had a protective efficacy of about 21 percent: 34 vaccinated people (48 percent) versus 37 placebo-group members (57 percent) developed symptoms.

While the study was a disappointment, Vaxart wasn’t ready to give up, arguing that the challenge study used large-dose exposures that people wouldn’t encounter in the real world.

“We use lots of copies of virus to ensure a high infection rate. In nature, 10 to 15 copies of virus is generally enough to give certain susceptible individuals disease,” James Cummings, chief medical officer at Vaxart, said in an investor call reported by Fierce Biotech at the time. “Field efficacy generally goes up, because the amount of inoculum that is causing disease that will be seen in the field is far lower than what is seen in the challenge study. My projection is that we would see an improvement in the decrease of [acute gastroenteritis] with our vaccine.”

Even a slight boost in efficacy could make the vaccine seem worthwhile. A 2012 modeling study suggested that even a vaccine with 50 percent efficacy could avert up to 2.2 million cases and save up to $2 billion over four years.

For now, we’ll have to wait to see what future trial data shows. And Vaxart’s vaccine isn’t the only one in the pipeline, nor is it the furthest along. Moderna has a norovirus vaccine in a Phase 3 trial, which is a larger study that will look at efficacy. But, while the trial is just beginning, Moderna noted in a financial update in February that the trial has been put on hold by the Food and Drug Administration due to a possible neurological side effect in one participant.

“The trial is currently on FDA clinical hold following a single adverse event report of a case of Guillain-Barré syndrome, which is currently under investigation,” Moderna reported. “The Company does not expect an impact on the study’s efficacy readout timeline as enrollment in the Northern Hemisphere has already been completed. The timing of the Phase 3 readout will be dependent on case accruals.”

Norovirus vaccine hints at defusing explosive stomach bug in early trial Read More »